[go: up one dir, main page]

CY1111672T1 - Παραγωγα αντιγονου σχετιζομενα με ογκους απο την οικογενεια των mage, τα οποια χρησιμοποιουνται για την παρασκευη πρωτεϊνων συντηξης με τ βοηθητικα επιτοπα και συνθεσεων για εμβολιασμο - Google Patents

Παραγωγα αντιγονου σχετιζομενα με ογκους απο την οικογενεια των mage, τα οποια χρησιμοποιουνται για την παρασκευη πρωτεϊνων συντηξης με τ βοηθητικα επιτοπα και συνθεσεων για εμβολιασμο

Info

Publication number
CY1111672T1
CY1111672T1 CY20111100663T CY111100663T CY1111672T1 CY 1111672 T1 CY1111672 T1 CY 1111672T1 CY 20111100663 T CY20111100663 T CY 20111100663T CY 111100663 T CY111100663 T CY 111100663T CY 1111672 T1 CY1111672 T1 CY 1111672T1
Authority
CY
Cyprus
Prior art keywords
producers
antigen
preparation
volume used
mage family
Prior art date
Application number
CY20111100663T
Other languages
English (en)
Inventor
Silva Teresa Cabezon
Joseph Cohen
Moncef M Slaoui
Bassols Carlota Vinals
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802543.0A external-priority patent/GB9802543D0/en
Priority claimed from GBGB9802650.3A external-priority patent/GB9802650D0/en
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1111672T1 publication Critical patent/CY1111672T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση αφορά νέες πρωτεΐνες και την παρασκευή τους, από την οικογένεια MAGE. Πιο συγκεκριμένα, μια πρωτεΐνη MAGE, συντηγμένη σε έναν ανοσολογικό εταίρο σύντηξης, όπως η Λιποπρωτεΐνη D. Τέτοια αντιγόνα μπορούν να διατυπωθούν ώστε να παράσχουν εμβόλια για την αντιμετώπιση ενός εύρος όγκων. Επίσης παρουσιάζονται νέες μέθοδοι για τον καθαρισμό των πρωτεϊνών MAGE.
CY20111100663T 1998-02-05 2011-07-08 Παραγωγα αντιγονου σχετιζομενα με ογκους απο την οικογενεια των mage, τα οποια χρησιμοποιουνται για την παρασκευη πρωτεϊνων συντηξης με τ βοηθητικα επιτοπα και συνθεσεων για εμβολιασμο CY1111672T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9802543.0A GB9802543D0 (en) 1998-02-05 1998-02-05 Vaccine
GBGB9802650.3A GB9802650D0 (en) 1998-02-06 1998-02-06 Vaccine
EP05076599A EP1584685B1 (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with T-helper epitopes and of compositions for vaccination

Publications (1)

Publication Number Publication Date
CY1111672T1 true CY1111672T1 (el) 2015-10-07

Family

ID=26313069

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20061100310T CY1105685T1 (el) 1998-02-05 2006-03-07 Συνδεομενα με ογκους αντιγονικα παραγωγα απο την οικογενεια mage, και ακολουθιες νουκλεϊκων οξεων που τα κωδικοποιουν, χρησιμοποιουμενα στην παρασκευη πρωτεϊνων συντηξης και συνθεσεων για εμβολιασμο
CY20101100509T CY1110180T1 (el) 1998-02-05 2010-06-10 Μεθοδος για τον καθαρισμο ή την παραγωγη μιας mage πρωτεϊνης
CY20111100663T CY1111672T1 (el) 1998-02-05 2011-07-08 Παραγωγα αντιγονου σχετιζομενα με ογκους απο την οικογενεια των mage, τα οποια χρησιμοποιουνται για την παρασκευη πρωτεϊνων συντηξης με τ βοηθητικα επιτοπα και συνθεσεων για εμβολιασμο
CY20111100885T CY1111831T1 (el) 1998-02-05 2011-09-14 Παραγωγα ογκο-συναφους αντιγονου απο την οικογενεια mage και αλληλουχιες νουκλεϊνικου οξεος που κωδικοποιουν αυτα, που χρησιμοποιουνται για την παρασκευη πρωτεϊνων συντηξης και συνθεσεων για εμβολιασμο

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20061100310T CY1105685T1 (el) 1998-02-05 2006-03-07 Συνδεομενα με ογκους αντιγονικα παραγωγα απο την οικογενεια mage, και ακολουθιες νουκλεϊκων οξεων που τα κωδικοποιουν, χρησιμοποιουμενα στην παρασκευη πρωτεϊνων συντηξης και συνθεσεων για εμβολιασμο
CY20101100509T CY1110180T1 (el) 1998-02-05 2010-06-10 Μεθοδος για τον καθαρισμο ή την παραγωγη μιας mage πρωτεϊνης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20111100885T CY1111831T1 (el) 1998-02-05 2011-09-14 Παραγωγα ογκο-συναφους αντιγονου απο την οικογενεια mage και αλληλουχιες νουκλεϊνικου οξεος που κωδικοποιουν αυτα, που χρησιμοποιουνται για την παρασκευη πρωτεϊνων συντηξης και συνθεσεων για εμβολιασμο

Country Status (25)

Country Link
US (3) US8097257B2 (el)
EP (4) EP1659179B1 (el)
JP (2) JP4768121B2 (el)
KR (2) KR100824105B1 (el)
CN (1) CN1227360C (el)
AR (1) AR018064A1 (el)
AT (4) ATE513042T1 (el)
AU (1) AU737337B2 (el)
BR (1) BR9907691B1 (el)
CA (2) CA2319309C (el)
CY (4) CY1105685T1 (el)
CZ (2) CZ298347B6 (el)
DE (3) DE69942214D1 (el)
DK (4) DK1053325T3 (el)
ES (2) ES2255248T3 (el)
HU (1) HU228467B1 (el)
IL (4) IL137442A0 (el)
NO (2) NO328507B1 (el)
NZ (1) NZ506086A (el)
PT (4) PT1659179E (el)
SA (1) SA99200126B1 (el)
SI (4) SI1659178T1 (el)
TR (1) TR200002284T2 (el)
TW (1) TWI238853B (el)
WO (1) WO1999040188A2 (el)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1659179E (pt) 1998-02-05 2011-09-16 Glaxosmithkline Biolog Sa Derivados de antigénios associados a tumor da família mage e sequências de ácidos nucleicos codificando-os, utilizados para a preparação de proteínas de fusão e de composições para vacinação
EP1502602A3 (en) * 1998-10-05 2006-05-17 Pharmexa A/S Methods for therapeutic vaccination
ES2222728T3 (es) 1998-10-05 2005-02-01 Pharmexa A/S Procedimiento de vacunacion terapeutica.
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
WO2001062778A2 (en) * 2000-02-23 2001-08-30 Smithkline Beecham Biologicals S.A. Tumour-specific animal proteins
ATE398463T1 (de) * 2000-04-13 2008-07-15 Corixa Corp Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
ATE513913T1 (de) 2000-05-10 2011-07-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
AUPQ761200A0 (en) 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
EP2182005B1 (en) * 2000-06-05 2015-03-25 The Brigham & Women's Hospital, Inc. A gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-21 and uses thereof
DK2133100T3 (da) 2000-06-20 2012-01-23 Corixa Corp MTB32A-Antigen af Mycobacterium tuberculosis med inaktiveret aktivt sted og fusionsproteiner deraf
PL208755B1 (pl) * 2000-10-18 2011-06-30 Glaxosmithkline Biolog Sa Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu
PT1326638E (pt) 2000-10-18 2008-02-06 Glaxosmithkline Biolog Sa Vacinas contra cancros
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
AU2002364161A1 (en) 2001-12-12 2003-06-23 Aventis Pasteur Limited Enhancement of the immune response using cd36-binding domain
EP1925626A1 (en) 2003-07-21 2008-05-28 Transgene S.A. Novel multifunctional cytokines
CA2537140A1 (en) * 2003-08-29 2005-03-10 The Nottingham Trent University Gastric and prostate cancer associated antigens
EP1670509A4 (en) * 2003-09-03 2007-10-31 Dendritherapeutics Inc MULTIPLEX VACCINES
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
WO2006104890A2 (en) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
KR20120089475A (ko) 2005-04-29 2012-08-10 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 결핵균 감염을 예방 또는 치료하기 위한 신규한 방법
EP1885847B1 (en) * 2005-05-26 2011-07-06 Cytos Biotechnology AG Scalable fermentation process
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
EP1951891B1 (en) * 2005-11-14 2012-02-15 Université Laval Cancer antigen mage-a9 and uses thereof
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
JP5170976B2 (ja) 2006-04-11 2013-03-27 株式会社イミュノフロンティア タンパク質複合体およびその製造方法
EP2390364A1 (en) 2006-06-02 2011-11-30 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy based on the differnetial expression of the PRKCQ gene
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
EP2484375B1 (en) 2006-09-26 2018-05-23 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy
WO2008087102A1 (en) * 2007-01-15 2008-07-24 Glaxosmithkline Biologicals Sa Vaccine
JP2010539065A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのペプチドの使用
WO2009033769A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of cortistatin 14 and others as a therapeutic agent
MX2010002965A (es) 2007-09-17 2010-09-14 Oncomethylome Sciences Sa Deteccion mejorada de la expresion de mage-a.
ATE553774T1 (de) * 2007-10-19 2012-05-15 Novartis Ag Meningokokkenimpfstoffformulierungen
CN102575284A (zh) 2009-03-17 2012-07-11 MDx健康公司 改进的基因表达检测
WO2010136443A1 (en) 2009-05-27 2010-12-02 Glaxosmithkline Biologicals S.A. Casb7439 constructs
RU2732574C2 (ru) 2009-06-05 2020-09-21 Инфекшес Дизиз Рисерч Инститьют Синтетические глюкопиранозиллипидные адъюванты
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
LT2528621T (lt) 2010-01-27 2016-12-12 Glaxosmithkline Biologicals S.A. Modifikuoti tuberkuliozės antigenai
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
EA201391183A1 (ru) 2011-02-15 2014-02-28 Иммьюн Дизайн Корп. Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
MX350795B (es) 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
CN102251034B (zh) * 2011-07-05 2012-11-21 北京大学人民医院 基于mage-c2/ct10基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
HUE042327T2 (hu) 2011-08-30 2019-06-28 Astex Pharmaceuticals Inc Decitabin-származék készítmények
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
CA2859799A1 (en) * 2011-12-22 2013-06-27 Glaxosmithkline Llc Method of treating cancer with magea3 immunotherapeutic with braf inhibitor and/or mek inhibitor
CN110339160A (zh) 2012-02-07 2019-10-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
DK2850431T3 (en) 2012-05-16 2018-07-16 Immune Design Corp Vaccines against HSV-2
CN109134640A (zh) 2012-10-23 2019-01-04 爱默蕾大学 Gm-csf和il-4轭合物、组合物以及与其相关的方法
CN110448566A (zh) 2013-03-01 2019-11-15 阿斯泰克斯制药公司 药物组合
EA032326B1 (ru) 2013-04-18 2019-05-31 Иммьюн Дизайн Корп. Монотерапия gla для применения в лечении рака
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
EP3089754B1 (en) 2013-12-31 2021-04-21 Infectious Disease Research Institute Single vial vaccine formulations
ES2738582T3 (es) 2014-02-14 2020-01-23 Immune Design Corp Inmunoterapia del cáncer a través de combinación de inmunoestimulación local y sistémica
US20170196954A1 (en) 2014-07-15 2017-07-13 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
HK1254645A1 (zh) 2015-07-02 2019-07-26 Otsuka Pharmaceutical Co., Ltd. 冻乾药物组合物
CN105181966B (zh) * 2015-09-02 2017-08-11 南通大学附属医院 一种mage‑a9的用途
KR102566134B1 (ko) 2015-12-07 2023-08-10 삼성전자주식회사 반도체 소자의 3d 프로파일링 시스템 및 이의 동작 방법
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
EP3443123B1 (en) 2016-04-11 2021-08-11 Board of Regents, The University of Texas System Methods and compositions for detecting single t cell receptor affinity and sequence
BR112018073690B1 (pt) 2016-05-16 2022-05-24 Infectious Disease Research Institute Formulação contendo agonista de tlr e métodos de uso
KR102483033B1 (ko) 2016-05-16 2022-12-30 액세스 투 어드밴스드 헬스 인스티튜트 페길화된 리포솜 및 이의 용도
MX393217B (es) 2016-06-01 2025-03-11 Infectious Disease Res Inst Particulas de nanoalumbre que contienen un agente de dimensionamiento
EP3638207B1 (en) 2017-06-15 2024-12-18 Access to Advanced Health Institute Nanostructured lipid carriers and stable emulsions and uses thereof
SG11202000932XA (en) 2017-08-03 2020-02-27 Otsuka Pharma Co Ltd Drug compound and purification methods thereof
AU2018330165B2 (en) 2017-09-08 2025-07-17 Access To Advanced Health Institute Liposomal formulations comprising saponin and methods of use
MA52536A (fr) 2018-04-19 2021-02-24 Baylor College Medicine Reprogrammation de lymphocytes t cd4 en lymphocytes cd8 cytotoxiques par expression forcée de récepteurs de lymphocytes t restreints à cd8ab et de classe 1
CN113286813A (zh) 2018-11-19 2021-08-20 得克萨斯大学体系董事会 用于car和tcr转导的模块化多顺反子载体
KR20210096638A (ko) 2018-11-28 2021-08-05 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 억제성 환경에 대한 기능 및 내성을 증진시키기 위한 면역 세포의 멀티플렉스 게놈 편집
EP4471129A3 (en) 2018-11-29 2025-02-19 Board of Regents, The University of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
US12318436B2 (en) 2019-05-25 2025-06-03 Access To Advanced Health Institute Composition and method for spray drying an adjuvant vaccine emulsion
US20230106973A1 (en) 2020-02-17 2023-04-06 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
CA3179694A1 (en) * 2020-04-17 2021-10-21 The Francis Crick Institute Limited Fusion proteins of ctl antigens for treating melanoma
AU2021335334A1 (en) 2020-09-04 2023-04-20 Access To Advanced Health Institute Genetically-adjuvanted rna vaccines
WO2022051022A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Co-lyophilized rna and nanostructured lipid carrier
WO2022104109A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
EP4251645A1 (en) 2020-11-25 2023-10-04 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
CN117120087A (zh) 2020-12-23 2023-11-24 高级健康研究所 茄尼醇疫苗助剂及其制备方法
JP2024514942A (ja) 2021-04-22 2024-04-03 ベイラー カレッジ オブ メディスン 殺夾雑活性を低下させた免疫細胞を工学的に作製する方法
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
WO2023089556A1 (en) 2021-11-22 2023-05-25 Pfizer Inc. Reducing risk of antigen mimicry in immunogenic medicaments
US20250235478A1 (en) 2022-04-28 2025-07-24 Musc Foundation For Research Development Chimeric antigen receptor modified regulatory t cells for treating cancer
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526716A (en) 1981-11-20 1985-07-02 The Ohio State University Antigenic modification of polypeptides
US4384995A (en) 1980-01-16 1983-05-24 The Ohio State University Antigenic modification of polypeptides
US4302386A (en) 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
AR241713A1 (es) 1984-08-30 1992-11-30 Smithkline Beckman Corp Molecula de dna con una secuencia de bases que codifica la proteina c13 y preparacion de vacunas contra la gripe.
ZA896627B (en) * 1988-08-31 1991-03-27 Smithkline Beecham Corp Vaccinal polypeptides
GB8824496D0 (en) 1988-10-19 1988-11-23 Beecham Group Plc Process
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
CA2022752C (en) 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
SE466259B (sv) * 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ES2055611T3 (es) 1990-07-23 1994-08-16 Zymogenetics Inc Pdgf resistente a proteasas y metodos de uso.
US5925729A (en) 1991-05-23 1999-07-20 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
DE69233474T2 (de) 1991-11-14 2006-03-30 The Brigham And Women's Hospital Inc., Boston Pharmazeutische Zusammensetzung enthaltend S-Nitrosoimmunoglobuline und Verwendung davon
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
GB9213559D0 (en) * 1992-06-25 1992-08-12 Smithkline Beecham Biolog Vaccines
ES2225824T3 (es) 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
AU702517B2 (en) * 1993-08-06 1999-02-25 Epimmune, Inc. Cloning and characterization of the complete MAGE-1 gene
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE209690T1 (de) 1994-03-01 2001-12-15 Ludwig Inst Cancer Res Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage
US5879687A (en) * 1994-04-22 1999-03-09 Corixa Corporation Methods for enhancement of protective immune responses
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
EP0782453A1 (en) * 1994-09-30 1997-07-09 Ludwig Institute For Cancer Research Compositions containing tumor rejection antigen precursors or tumor rejection antigens, and an adjuvant and/or growth factor
US5612030A (en) * 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US6017705A (en) 1995-03-14 2000-01-25 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-B family and uses thereof
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
WO1997001574A1 (en) 1995-06-29 1997-01-16 Ludwig Institute For Cancer Research Isolated nucleic acid molecule which encodes murine tumor rejection antigen precursor smage-3
WO1997013858A2 (en) 1995-10-12 1997-04-17 Chiron Corporation Baboon mage-3 homologs, dna encoding the homologs, and a process for their use
US6265215B1 (en) 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
US5908778A (en) 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
US6030780A (en) 1996-10-15 2000-02-29 The Rockefeller University Purified Stat proteins and methods of purifying thereof
EP0941366A2 (en) 1996-11-06 1999-09-15 Whitehead Institute For Biomedical Research Biallelic markers
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
WO1998026747A2 (en) 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases
US6287569B1 (en) 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
US20020176865A1 (en) 1997-04-25 2002-11-28 Sophie Lucas Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B families and uses thereof
US6027924A (en) 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6043084A (en) 1997-10-10 2000-03-28 Ludwig Institute For Cancer Research Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
PT1659179E (pt) 1998-02-05 2011-09-16 Glaxosmithkline Biolog Sa Derivados de antigénios associados a tumor da família mage e sequências de ácidos nucleicos codificando-os, utilizados para a preparação de proteínas de fusão e de composições para vacinação
AU3371199A (en) 1998-04-09 1999-11-01 Whitehead Institute For Biomedical Research Biallelic markers
US6686147B1 (en) 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor

Also Published As

Publication number Publication date
EP1053325A2 (en) 2000-11-22
US20100204458A1 (en) 2010-08-12
WO1999040188A3 (en) 1999-10-14
CZ298347B6 (cs) 2007-09-05
DK1053325T3 (da) 2006-05-22
HK1033838A1 (en) 2001-09-28
IL188875A (en) 2011-08-31
SI1659179T1 (sl) 2011-10-28
PT1053325E (pt) 2006-05-31
HK1093521A1 (en) 2007-03-02
ATE462788T1 (de) 2010-04-15
EP1584685B1 (en) 2011-04-13
IL137442A (en) 2008-04-13
NO20091665L (no) 2000-10-04
SI1659178T1 (sl) 2010-07-30
AU737337B2 (en) 2001-08-16
EP1659179A3 (en) 2007-01-17
ATE505542T1 (de) 2011-04-15
DE69942214D1 (de) 2010-05-12
KR20010040675A (ko) 2001-05-15
IL137442A0 (en) 2001-07-24
PT1659178E (pt) 2010-06-28
EP1659178A3 (en) 2007-01-17
KR20060067977A (ko) 2006-06-20
JP4768121B2 (ja) 2011-09-07
IL188875A0 (en) 2009-02-11
TWI238853B (en) 2005-09-01
EP1584685A3 (en) 2005-12-07
HUP0102639A1 (hu) 2001-11-28
ES2255248T3 (es) 2006-06-16
KR100633212B1 (ko) 2006-10-11
CN1227360C (zh) 2005-11-16
CZ20002869A3 (cs) 2001-01-17
CY1110180T1 (el) 2015-01-14
ES2342416T3 (es) 2010-07-06
CA2319309A1 (en) 1999-08-12
EP1659179A2 (en) 2006-05-24
NO20003958D0 (no) 2000-08-04
BR9907691A (pt) 2000-11-14
PT1659179E (pt) 2011-09-16
JP2002502604A (ja) 2002-01-29
CA2319309C (en) 2010-08-10
DE69929310T2 (de) 2006-08-03
NO331719B1 (no) 2012-03-05
CZ298364B6 (cs) 2007-09-05
US8597656B2 (en) 2013-12-03
HU228467B1 (en) 2013-03-28
NO20003958L (no) 2000-10-04
NO328507B1 (no) 2010-03-08
DE69943359D1 (de) 2011-05-26
BR9907691B1 (pt) 2011-05-31
EP1659178A2 (en) 2006-05-24
SA99200126B1 (ar) 2006-08-20
US8044183B2 (en) 2011-10-25
US20100209444A1 (en) 2010-08-19
EP1659178B1 (en) 2010-03-31
DE69929310D1 (de) 2006-03-30
EP1053325B1 (en) 2006-01-04
EP1659179B1 (en) 2011-06-15
NZ506086A (en) 2003-01-31
PL342852A1 (en) 2001-07-16
CN1295616A (zh) 2001-05-16
EP1584685A2 (en) 2005-10-12
HK1093522A1 (en) 2007-03-02
WO1999040188A2 (en) 1999-08-12
ATE513042T1 (de) 2011-07-15
CY1111831T1 (el) 2015-10-07
AU2722099A (en) 1999-08-23
CA2584482A1 (en) 1999-08-12
HUP0102639A3 (en) 2004-04-28
DK1584685T3 (da) 2011-07-11
DK1659178T3 (da) 2010-07-12
US8097257B2 (en) 2012-01-17
PT1584685E (pt) 2011-06-17
TR200002284T2 (tr) 2000-11-21
DK1659179T3 (da) 2011-10-10
HK1083026A1 (en) 2006-06-23
JP2009201510A (ja) 2009-09-10
SI1584685T1 (sl) 2011-07-29
US20120269835A1 (en) 2012-10-25
CA2584482C (en) 2012-03-27
KR100824105B1 (ko) 2008-04-21
SI1053325T1 (sl) 2006-06-30
AR018064A1 (es) 2001-10-31
CY1105685T1 (el) 2010-12-22
IL179010A0 (en) 2007-03-08
ATE315088T1 (de) 2006-02-15

Similar Documents

Publication Publication Date Title
CY1111672T1 (el) Παραγωγα αντιγονου σχετιζομενα με ογκους απο την οικογενεια των mage, τα οποια χρησιμοποιουνται για την παρασκευη πρωτεϊνων συντηξης με τ βοηθητικα επιτοπα και συνθεσεων για εμβολιασμο
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1122686T1 (el) Ανταγωνιστικοι εκλεκτικοι παραγοντες συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης
CY1108545T1 (el) Πρωτεϊνες υπομοναδας υποδοχεα κυτοκινης θηλαστικου, σχετικα αντιδραστηρια και μεθοδοι
SI0970126T1 (en) Novel method for the production of antihuman antigen receptors and uses thereof
CY1109664T1 (el) Πρωτεϊνες δεσμευσεως ιντερλευκινης-18, η παρασκευη και η χρηση τους
CY1113298T1 (el) Ανασυνδυασμενα αντισωματα υψηλης ισχυος και μεθοδος παραγωγης αυτων
DK121683D0 (da) Fremgangsmade til fremstilling af immunoenzymatiske konjugater
CY1107570T1 (el) Ανοσογονικα πολυπεπτιδια κωδικοποιουμενα απο μινιγονιδια mage και οι χρησεις τους
ATE298798T1 (de) Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
DE60025832D1 (de) Mehrere zytokin-antikörper komplexen
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
FI935795A0 (fi) CTL4A-receptor, fusionsproteiner innehaollande denna och anvaendningar daerav
TR200001946T2 (tr) Aşı
NO963018L (no) CTLA4-mutantmolekyler og anvendelser derav
AP2001002199A0 (en) Novel streptococcus antigens
DE69939897D1 (de) Entwicklung von menschlichen monoklonalen antikörpern und deren gebrauch
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
ES2042461T1 (es) Producto y procedimiento para el te\ido oxidativo del cabello.
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
AU2911289A (en) Carcinoma-associated antigens, and antibodies which recognize these antigens
WO2001004143A3 (en) Prostase vaccine
ES2058113T3 (es) Metodo de preparacion y uso de antigenos de virus de leucemia felina.